Back
Alkermes Plc 10K Form
Sell
49
ALKS
Alkermes Plc
Last Price:
$34.82
Seasonality Move:
1.6%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-01 | 10Q | ALKS/Alkermes Plc Quarterly |
| 2023-10-25 | 10Q | ALKS/Alkermes Plc Quarterly |
| 2023-07-26 | 10Q | ALKS/Alkermes Plc Quarterly |
| 2023-04-26 | 10Q | ALKS/Alkermes Plc Quarterly |
| 2022-11-02 | 10Q | ALKS/Alkermes Plc Quarterly |
| 2022-07-27 | 10Q | ALKS/Alkermes Plc Quarterly |
Receive ALKS News And Ratings
See the #1 stock for the next 7 days that we like better than ALKS
ALKS Financial Statistics
Sales & Book Value
| Annual Sales: | $1.5B |
|---|---|
| Cash Flow: | $170.1M |
| Price / Cash Flow: | 12.24 |
| Annual Sales: | $10.99 |
| Price / Book: | 3.19 |
Profitability
| EPS (TTM): | 1.43250 |
|---|---|
| Net Income (TTM): | $241.7M |
| Gross Margin: | $1.3B |
| Return on Equity: | 14.82% |
| Return on Assets: | 10.74% |
Alkermes Plc Earnings Forecast
Key Alkermes Plc Financial Ratios
-
The Gross Profit Margin over the past 36 years for ALKS is 86.31%.
-
The Selling, General & Administrative Expenses for ALKS have been equal to 47.53% of Gross Profit Margin.
-
The Research & Development expenses have been 21.57% of Revenue.
-
The Interest Expense is 5.08% of Operating Income.
-
The Net Earning history of ALKS is 16.37% of Total Revenues.
-
Per Share Earnings over the last 36 years have been positive in 18 years.
Alkermes Plc Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALKS |
| CUSIP: | G01767 |
| Website: | alkermes.com |
Debt
| Debt-to-Equity Ratio: | 0.04 |
|---|---|
| Current Ratio: | 3.55 |
| Quick Ratio: | 3.04 |
Price-to-Earnings
| Trailing P/E Ratio: | 24.33 |
|---|---|
| Forward P/E Ratio: | 17.47 |
ALKS Technical Analysis vs Fundamental Analysis
Sell
49
Alkermes Plc (ALKS)
is a Sell
Is Alkermes Plc a Buy or a Sell?
-
Alkermes Plc stock is rated a SellThe current Alkermes Plc [ALKS] share price is $34.84. The Score for ALKS is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.